MSME (Udyam registered) Ministry of MSME
- Category
- Micro (2024-25)
- Udyam number
- UDYAM-KR-03-0154754
Icrest Biotechnologies Limited - healthcare in Bangalore, Karnataka, India. FY 2026 financials & compliance.
Revenue · FY 2025
₹1.68 Cr
▲ 38% YoY
Net profit · FY 2025
₹3.03 Lakh
Net margin 1.8%
EBITDA · FY 2025
₹17.59 Lakh
EBITDA margin 10.4%
Authorised capital
₹2 Cr
Registered with MCA
Paid-up capital
₹1.34 Cr
Issued & subscribed
Open charges
₹68.53 Lakh
Satisfied ₹27.65 Lakh
Company age
18 yrs
Est. 2008
Directors on board
5
As per MCA filings
About Icrest Biotechnologies Limited
Data last updated:
Icrest Biotechnologies Limited is a public limited company based in Bangalore, Karnataka, India. It operates in the preventive healthcare segment of the healthcare sector. It was incorporated on 17 September 2008 and has been in existence for over 18 years.
Its director BS Ajaikumar is #1,482 on the Hurun India Rich List 2026.
The company is registered with the Registrar of Companies (ROC), Bangalore, under CIN U33100KA2008PLC047800.
The company has an authorised share capital of ₹2 Cr and a paid-up capital of ₹1.34 Cr. It is led by directors including Gururaj Ananda Rao (Managing Director) and Jyothsna Ananda Rao (Whole-Time Director).
Its last annual general meeting (AGM) was held on 26 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at No.117 Venkateshapura Jakkur Post Yelahanka Hobli, Bangalore, Karnataka, India – 560064.
As per the financials filed for FY 2025, the company reported a revenue of ₹1.68 Cr, a growth of 38% compared to the previous year. For the same year it recorded a net profit of ₹3.03 Lakh (net margin 1.8%) and EBITDA of ₹17.59 Lakh (EBITDA margin 10.4%). Revenue has grown at a compounded annual rate (CAGR) of 34% over three years and 4% over five years.
The company is associated with 1 brand: International Stemcell Services. As per MCA filings, the company has open charges of ₹68.53 Lakh and satisfied charges of ₹27.65 Lakh on record. The company has 15 deals on record (8 secondary share transfers, 7 funding rounds), with disclosed funding of ₹79.8 Lakh; the latest was in April 2018. Its 10 peer companies in the Biotechnology industry (Biotechnology) are compared by revenue, 5 larger and 5 smaller; the largest is Mycelium Sona Biotech Private Limited with revenue of ₹1.75 Cr.
Icrest Biotechnologies Limited is registered as a micro enterprise under the Udyam registration framework (Reg. No. UDYAM-KR-03-0154754). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website internationalstemcellservices.com.
Company Details of Icrest Biotechnologies Limited
CIN U33100KA2008PLC047800
Registration Number 047800
Incorporation Date 17 September 2008
ROC Bangalore
Listing Status Unlisted
Company Status Active
Date of Last AGM 26 September 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
MSME Classification Micro
Udyam Registration UDYAM-KR-03-0154754
Key People
Gururaj Ananda Rao Managing Director Jyothsna Ananda Rao Whole-Time Director Gopalakrishna Sreemushanam Anandarao Director Recognitions & Rankings of Icrest Biotechnologies
Hurun India Rich List 2026 edition · 1 director
- #1,482 BS Ajaikumar ₹1,400 Cr
Contact Details
- EmailLocked
- TelephoneLocked
- Social MediaLocked
- Registered AddressNo.117 Venkateshapura Jakkur Post Yelahanka Hobli, Bangalore, Karnataka, India – 560064
- IndustryHealthcare, Preventive Health Services
Comprehensive company report
Icrest Biotechnologies Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Associated Brands with Icrest Biotechnologies Limited
Icrest Biotechnologies operates one associated brand: International Stemcell Services. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Provides storage of human adult stem cells | internationalstemcellservices.com |
Business Activity of Icrest Biotechnologies Limited
The main business activity of Icrest Biotechnologies is hospital and medical care. In detail, this covers other hospital and medical care activities.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities | Locked |
Premium access
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Icrest Biotechnologies Limited FY 2025 filings available
Icrest Biotechnologies Limited reported revenue of ₹1.68 Cr (up 38% YoY) for FY 2025.
Revenue · FY 2025
₹1.68 Cr ▲ 38%
Net profit · FY 2025
₹3.03 Lakh margin 1.8%
EBITDA · FY 2025
₹17.59 Lakh margin 10.4%
Compounded Annual Growth Rate (CAGR) of Icrest Biotechnologies Limited
Revenue CAGR growth
1 year
▲ 38%
3 years · compounded
▲ 34%
5 years · compounded
▲ 4%
EBITDA CAGR growth
1 year
▲ 38%
3 years · compounded
▲ 178%
5 years · compounded
▼ 3%
Revenue has grown at a compounded annual rate (CAGR) of 4% over five years, including 38% growth in the latest year. EBITDA rose 38% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Icrest Biotechnologies Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹17.59 Lakh | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹3.03 Lakh | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Icrest Biotechnologies Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 10.4% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.8% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Icrest Biotechnologies are in the company report.
Premium access
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Icrest Biotechnologies Limited
Icrest Biotechnologies has 5 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Gururaj Ananda Rao | Managing Director | 01 Dec 2010 | 15 Years 10 Months | Current |
| Gopalakrishna Sreemushanam Anandarao | Director | 17 Sep 2008 | 18 Years 1 Months | Current |
| Jyothsna Ananda Rao | Whole-Time Director | 17 Sep 2008 | 18 Years 1 Months | Current |
| Basavalinga Ajaikumar Sadasivaiah | Director | 28 Feb 2024 | 2 Years 7 Months | Current |
| Sunanda Ananda Rao Also directs: Sri Raghavendra Biotechnologies Private Limited | Director | 01 Mar 2010 | 16 Years 7 Months | Current |
Peer Comparison of Icrest Biotechnologies Limited
Icrest Biotechnologies Limited is compared with the companies closest to it by revenue in the Biotechnology industry (Biotechnology). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Mycelium Sona Biotech Private Limited | ₹1.75 Cr (FY 2025) | •••• | •••• | -62.0% | •••• | Bangalore, Karnataka, India |
| Toxiven Biotech Private Limited | ₹1.74 Cr (FY 2025) | •••• | •••• | 238.0% | •••• | Coimbatore, Tamil Nadu, India |
| Bioxcell Life Sciences Private Limited | ₹1.74 Cr (FY 2021) | •••• | •••• | -5.0% | •••• | Hyderabad, Telangana, India |
| Cosmo Felix Private Limited | ₹1.73 Cr (FY 2024) | •••• | •••• | 53.0% | •••• | Delhi, India |
| KDR Crop Science Private Limited | ₹1.7 Cr (FY 2025) | •••• | •••• | -6.0% | •••• | Ahmedabad, Gujarat, India |
| Icrest Biotechnologies Limited this company | ₹1.68 Cr (FY 2025) | •••• | •••• | 38.0% | •••• | Bangalore, Karnataka, India |
| Hams Biotech Private Limited | ₹1.68 Cr (FY 2024) | •••• | •••• | -42.0% | •••• | Chennai, Tamil Nadu, India |
| Srinidhi Biotech Private Limited | ₹1.68 Cr (FY 2024) | •••• | •••• | 10.0% | •••• | Gulbarga, Karnataka, India |
| Microbiological Laboratory Research and Services India Private Limited | ₹1.65 Cr (FY 2025) | •••• | •••• | 11.0% | •••• | Coimbatore, Tamil Nadu, India |
| Loopworm Private Limited | ₹1.65 Cr (FY 2024) | •••• | •••• | 92.0% | •••• | Bangalore, Karnataka, India |
| Tranalab Private Limited | ₹1.63 Cr (FY 2025) | •••• | •••• | 626.0% | •••• | Chinnappanahalli, Karnataka, India |
Peers are the five companies nearest above and the five nearest below Icrest Biotechnologies by revenue in the Biotechnology industry (Biotechnology), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Icrest Biotechnologies Limited
Icrest Biotechnologies Limited is audited by B N JAYARAM & CO for the financial year 2022.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| B N JAYARAM & CO | Locked | Locked | Locked |
Premium access
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Ownership and Shareholding of Icrest Biotechnologies Limited
Premium access
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Icrest Biotechnologies Limited
Open charges
₹68.53 Lakh
Satisfied charges
₹27.65 Lakh
Breakdown by lending institutions
Latest charge details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 24 Oct 2024 | Hdfc Bank Limited | ₹68.53 Lakh | Open |
| 05 Dec 2015 | Icici Bank Limited | ₹3.65 Lakh | Satisfied |
| 31 Dec 2013 | Corporation Bank | ₹24 Lakh | Satisfied |
Total charge records: 3 View all charges
Deals & Funding of Icrest Biotechnologies Limited
Icrest Biotechnologies Limited has 15 deals on record (8 secondary share transfers, 7 funding rounds), with disclosed funding of ₹79.8 Lakh; the latest was in April 2018.
Total deals
15
Secondary share transfers
8
Funding rounds
7
Disclosed funding
₹79.8 Lakh
Deals on record (5 of 15)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Apr 2018 | Secondary share transfer | Undisclosed | Buyer: Healthcare Global Enterprises Limited Seller: 4 individuals |
| Dec 2017 | Secondary share transfer | Undisclosed | Buyer: 4 individuals Seller: 4 individuals |
| Oct 2015 | Funding round | ₹22 Lakh | Investors: Sri Raghavendra Biotechnologies Private Limited , 3 individuals |
| Mar 2010 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Cryo Stemcell Private Limited , 3 individuals |
| Jul 2009 | Funding round | ₹12.5 Lakh | Investors: Cryo Stemcell Private Limited , 3 individuals |
Premium access
Full deal history
All 15 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Employees and EPFO Compliance at Icrest Biotechnologies Limited
Employment history and EPFO contributions of people linked to Icrest Biotechnologies.
Premium access
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Icrest Biotechnologies Limited
Icrest Biotechnologies Limited has 10 board changes on record since 2008: 5 appointments and 5 cessations. The latest: Basavalinga Ajaikumar Sadasivaiah was appointed as Director on 28 Feb 2024.
AGM
Icrest Biotechnologies Limited last Annual general meeting of members was held on 26 Sep 2025 as per latest MCA records.
Filing
Icrest Biotechnologies Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Bangalore.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 0.69 Cr with Charge ID 101016493 was registered on 24 Oct 2024.
Appointed
Basavalinga Ajaikumar Sadasivaiah was appointed as Director.
Ceased
Gopalakrishna Sreemushanam Anandarao ceased to be Whole-Time Director.
Ceased
Jyothsna Ananda Rao ceased to be Director.
Charges
A charge registered on 05 Dec 2015 via Charge ID 10619056 with Icici Bank Limited was fully satisfied on 28 Jan 2019.
Charges
A charge registered on 31 Dec 2013 via Charge ID 10473800 with Corporation Bank was fully satisfied on 09 Dec 2015.
Charges
A charge with Icici Bank Limited amounted to Rs. 0.04 Cr with Charge ID 10619056 was registered on 05 Dec 2015.
Charges
A charge with Corporation Bank amounted to Rs. 0.24 Cr with Charge ID 10473800 was registered on 31 Dec 2013.
Appointed
Gururaj Ananda Rao was appointed as Managing Director.
Ceased
Sunanda Ananda Rao ceased to be Additional Director.
6 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Icrest Biotechnologies Limited
Premium access
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Icrest Biotechnologies Limited
Premium access
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Icrest Biotechnologies Limited
Premium access
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Icrest Biotechnologies Limited
Premium access
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Icrest Biotechnologies Limited
Premium access
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Related news about Icrest Biotechnologies Limited
Frequently Asked Questions about Icrest Biotechnologies Limited
Icrest Biotechnologies is an active public limited company based in Bangalore, Karnataka, India. The company works in preventive health services, within the healthcare industry. It was incorporated on 17 September 2008 (18+ years old) and is registered under CIN U33100KA2008PLC047800.
Icrest Biotechnologies reported revenue of ₹1.68 Cr for FY 2025 (up 38% YoY).
Icrest Biotechnologies has 5 current directors:
- Gururaj Ananda Rao - Managing Director
- Jyothsna Ananda Rao - Whole-Time Director
- Gopalakrishna Sreemushanam Anandarao - Director
- Basavalinga Ajaikumar Sadasivaiah - Director
- Sunanda Ananda Rao - Director
Icrest Biotechnologies reported a net profit of ₹3.03 Lakh (net margin 1.8%) and EBITDA of ₹17.59 Lakh (EBITDA margin 10.4%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Icrest Biotechnologies is 34% over three years and 4% over five years. In the latest year (FY 2025) revenue rose 38%. CAGR is the steady yearly rate that links the first and the last year.
The CIN (Corporate Identification Number) of Icrest Biotechnologies is U33100KA2008PLC047800. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Icrest Biotechnologies was incorporated on 17 September 2008, making it 18+ years old. It is registered with the Registrar of Companies, Bangalore.
Icrest Biotechnologies has 15 deals on record (8 secondary share transfers, 7 funding rounds), with disclosed funding of ₹79.8 Lakh; the latest was in April 2018.
The peers of Icrest Biotechnologies by revenue are Mycelium Sona Biotech Private Limited, Toxiven Biotech Private Limited, Bioxcell Life Sciences Private Limited, Cosmo Felix Private Limited, KDR Crop Science Private Limited and 5 more, all in the Biotechnology industry (Biotechnology).
Basavalinga Ajaikumar Sadasivaiah was appointed as Director on 28 Feb 2024. Gopalakrishna Sreemushanam Anandarao ceased to be Whole-Time Director on 05 Sep 2022. Jyothsna Ananda Rao ceased to be Director on 05 Sep 2022. Icrest Biotechnologies has 10 board changes on record in total.
Yes, Icrest Biotechnologies is registered as a micro enterprise under Udyam registration (number: UDYAM-KR-03-0154754).